Maintenance Pembrolizumab for Metastatic Endometrial Cancer
Maintenance pembrolizumab following carboplatin-paclitaxel chemotherapy is strongly recommended for first-line treatment of advanced/metastatic endometrial cancer, with the most robust evidence supporting its use in mismatch repair-deficient (MMRd) tumors, though significant benefit also exists for mismatch repair-proficient (pMMR) disease.
Evidence-Based Treatment Algorithm
First-Line Treatment Setting
The 2025 ESGO-ESTRO-ESP guidelines provide the most current recommendations 1:
For MMRd tumors: Immune checkpoint inhibitors (pembrolizumab, dostarlimab, or durvalumab) combined with carboplatin-paclitaxel for 6 cycles, followed by immune checkpoint inhibitor maintenance therapy (Level I, Grade A evidence)
For pMMR tumors with rapidly growing or symptomatic disease: Carboplatin-paclitaxel chemotherapy is standard (Level I, Grade A), but immune checkpoint inhibitors plus chemotherapy followed by maintenance therapy (pembrolizumab or dostarlimab) can be considered (Level I, Grade B)
Key Supporting Trial Data
The NRG-GY018 trial provides the strongest evidence for pembrolizumab maintenance 2, 3, 4:
MMRd cohort (n=225):
- 1-year PFS: 74% with pembrolizumab vs 38% with placebo
- Hazard ratio: 0.30 (95% CI 0.19-0.48; p<0.001)
- Median PFS not reached with pembrolizumab vs 7.6 months with placebo
- This represents a 70% reduction in relative risk of progression or death
pMMR cohort (n=588):
- Median PFS: 13.1 months with pembrolizumab vs 8.7 months with placebo
- Hazard ratio: 0.54 (95% CI 0.41-0.71; p<0.001)
Treatment regimen: Pembrolizumab 200 mg every 3 weeks with chemotherapy for 6 cycles, followed by pembrolizumab 400 mg every 6 weeks for up to 14 maintenance cycles 2.
Mismatch Repair Status is Critical
You must determine MMR status before initiating therapy 1. This biomarker determines:
- Expected magnitude of benefit (dramatically higher in MMRd)
- Strength of recommendation (Level I, Grade A for MMRd vs Level I, Grade B for pMMR)
- Alternative treatment considerations
The 2023 SITC guidelines recommend immunohistochemistry as the first-line test for MMR status 2.
Safety Profile
From NRG-GY018 2:
- Grade ≥3 adverse events: 63.3% (MMRd cohort) and 55.1% (pMMR cohort) with pembrolizumab vs 47.2% and 45.3% with placebo
- Common adverse events (any grade): fatigue, peripheral sensory neuropathy, anemia, nausea
- Discontinuation rate due to adverse reactions: approximately 14-21% across studies 5
Second-Line Setting (Previously Treated Disease)
For patients who have not received prior immunotherapy 1:
MMRd tumors:
- Preferred: Pembrolizumab monotherapy (Level III, Grade A)
- Alternative: Pembrolizumab plus lenvatinib (Level I, Grade B)
pMMR tumors:
- Standard: Pembrolizumab plus lenvatinib (Level I, Grade A)
- KEYNOTE-775 data: Median OS 17.4 months vs 12 months with chemotherapy (HR 0.68; p=0.0001) 2
- 5-year OS rate: 16.7% with pembrolizumab-lenvatinib vs 7.3% with chemotherapy 6
Critical Clinical Considerations
Contraindications to assess:
- Active autoimmune disease requiring systemic therapy
- Medical conditions requiring immunosuppression
- History of severe immune-related adverse reactions
Duration of maintenance: Up to 14 cycles (approximately 2 years) in the maintenance phase after completing 6 cycles of combination therapy 2.
Monitoring requirements: Watch for immune-related adverse events including hypothyroidism (11.2%), hyperthyroidism (12%), pneumonitis (7%), hepatotoxicity (14%), and acute kidney injury (13%) 5.
Comparative Context
While dostarlimab (RUBY trial) and durvalumab also show efficacy in this setting 2, pembrolizumab has the advantage of:
- FDA approval for this indication 5
- Longer follow-up data (5-year outcomes available for pembrolizumab-lenvatinib combination) 6
- Established dosing regimens in both first and second-line settings
The evidence unequivocally supports maintenance pembrolizumab following chemotherapy as standard of care for first-line treatment of advanced/metastatic endometrial cancer, particularly in MMRd disease where the benefit is most pronounced.